Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Long-term Mitapivat Dosing in Subjects With Stable Sickle Cell Disease: An Extension of a Phase I Pilot Study of Mitapivat

NCT04610866 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

15

Enrollment

NIH

Sponsor class

Conditions

Sickle Cell Disease
Hemolytic Anemia

Interventions

DRUG: Mitapivat

Sponsor

National Heart, Lung, and Blood Institute (NHLBI)